Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Consensus "Moderate Buy": Eight analysts cover Oculis (7 buy, 1 sell) with an average 12‑month price target of about $43.86.
• Several brokers have recently raised targets or initiated coverage—e.g., Stifel to $50, Lifesci to $55 (outperform), HC Wainwright to $44, and JPMorgan started with an overweight/$38 target—signaling growing analyst interest.
• Quarterly results show continuing losses (EPS -$0.51, missing estimates) despite $0.5M revenue; the company remains unprofitable with a projected FY EPS of -2.09, a market cap of $1.45B, and a 12‑month trading range of $14.00–$30.68.

Shares of Oculis Holding AG (NASDAQ:OCS - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $43.8571.

Several brokerages recently commented on OCS. Stifel Nicolaus upped their target price on Oculis from $40.00 to $50.00 and gave the company a "buy" rating in a research report on Wednesday, March 4th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Oculis in a report on Thursday, January 22nd. HC Wainwright increased their price target on Oculis from $42.00 to $44.00 and gave the stock a "buy" rating in a report on Wednesday, March 4th. Lifesci Capital assumed coverage on shares of Oculis in a research report on Wednesday, December 3rd. They set an "outperform" rating and a $55.00 price objective for the company. Finally, JPMorgan Chase & Co. began coverage on shares of Oculis in a research note on Friday, December 19th. They issued an "overweight" rating and a $38.00 price objective for the company.

Institutional Investors Weigh In On Oculis

Hedge funds and other institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. boosted its position in shares of Oculis by 100.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company's stock worth $40,000 after purchasing an additional 1,000 shares in the last quarter. Aventura Private Wealth LLC bought a new stake in Oculis in the 4th quarter valued at about $80,000. Millennium Management LLC acquired a new position in Oculis during the 4th quarter worth approximately $312,000. Bosun Asset Management LLC acquired a new position in Oculis during the 2nd quarter worth approximately $378,000. Finally, Marshall Wace LLP bought a new position in Oculis in the second quarter worth approximately $393,000. 22.30% of the stock is owned by institutional investors.

Oculis Trading Down 0.0%

OCS opened at $24.99 on Friday. The stock has a market cap of $1.45 billion, a PE ratio of -11.01 and a beta of 0.29. The company has a quick ratio of 5.96, a current ratio of 5.96 and a debt-to-equity ratio of 0.01. Oculis has a twelve month low of $14.00 and a twelve month high of $30.68. The company has a fifty day moving average of $27.44 and a 200-day moving average of $22.42.

Oculis (NASDAQ:OCS - Get Free Report) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.08). Oculis had a negative net margin of 8,173.41% and a negative return on equity of 62.12%. The firm had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.14 million. On average, sell-side analysts predict that Oculis will post -2.09 EPS for the current year.

Oculis Company Profile

Oculis SA NASDAQ: OCS is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.